Atossa Therapeutics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Atossa Therapeutics, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Self-Funding Ratio: Over the last 3 years operating cash was negative while the company kept spending on investment (capex). Lower than almost all Healthcare companies in United States.
- Steadiness Ratio: Sales grew in 0 of the last 3 years; profit grew in 1 of 3. Less steady than 86% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
-1,280.9×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than almost all Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 1/3Sales grew in 0 of the last 3 years; profit grew in 1 of 3.
Less steady than 86% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
—Data incomplete
Cash Cushion Ratio
—Data incomplete
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (9)
Atossa Therapeutics, Inc. made a loss over the last year. Atossa Therapeutics, Inc. owes $0.17 for every $1 it owns. Atossa Therapeutics, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossAtossa Therapeutics, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
1.01The share price is 1.01 times Atossa Therapeutics, Inc.'s book value per share, lower than 78% of Healthcare companies in United States.
Market cap
$27 MThe total market value of all of Atossa Therapeutics, Inc.'s shares at today's price (share price × number of shares), smaller than 80% of Healthcare companies in United States. PosiCap size class: Micro Cap.
Net worth (book value)
$27 MWhat Atossa Therapeutics, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$2.69Net worth divided by the number of shares. The share price of $2.72 is 1.0 times this, which is the P/B above.
Return on equity (ROE)
-89.2%Atossa Therapeutics, Inc. lost 89.2% of its shareholders' money over the last year, lower than 68% of Healthcare companies in United States.
Owes vs Owns
0.17×Atossa Therapeutics, Inc. owes $0.17 for every $1 it owns (low), lower than 77% of Healthcare companies in United States.
Dividend yield
NoneAtossa Therapeutics, Inc. does not currently pay a dividend.
Profit growth
LossAtossa Therapeutics, Inc. made a loss in each of the last two years.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Atossa Therapeutics, Inc.: $27 M ÷ $27 M (30 Jun 2026) = 1.0.
What is Atossa Therapeutics, Inc.'s return on equity?
Atossa Therapeutics, Inc. lost 89.2% of its shareholders' money over the last year, lower than 68% of Healthcare companies in United States.
How much does Atossa Therapeutics, Inc. owe compared with what it owns?
Atossa Therapeutics, Inc. owes $0.17 for every $1 it owns (low), lower than 77% of Healthcare companies in United States.
Does Atossa Therapeutics, Inc. pay a dividend?
No. Atossa Therapeutics, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.